{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:35:57Z","timestamp":1791351357322,"version":"4.3.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,5,2]]},"DOI":"10.1080\/14656566.2024.2360069","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:23:01Z","timestamp":1717082581000},"page":"791-799","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer\u2019s disease: a novel small molecule with disease modifying potential"],"prefix":"10.1080","volume":"25","author":[{"given":"Daniel","family":"Lee","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Disease Care, Research and Education (AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga M.","family":"Antonsdottir","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Nursing, Baltimore, MD, USA"},{"name":"Richman Family Precision Medicine Center of Excellence in Alzheimer\u2019s Disease, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview, Johns Hopkins Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Clark","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Care, Research and Education (AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Care, Research and Education (AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0909142"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.23"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2195539"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90609-V"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-030421-112756"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18325-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.440"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550160069041"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.52"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.06.015"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8346443"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00375-6"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3983"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.733857"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00292-3"},{"key":"e_1_3_4_24_1","unstructured":"LEQEMBITM (lecanemab-irmb). package insert. Nutley (NJ): Eisai Inc.; 2023 [cited 2023 Feb 3]. Available from: https:\/\/www.leqembi.com\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf?hash=3d7bf1a2-5db2-4990-8388-81086f415676"},{"key":"e_1_3_4_25_1","unstructured":"Biogen. Biogen to realign resources for Alzheimer\u2019s disease franchise 2024 [updated Jan 31] [cited 2024 Feb 28]. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-realign-resources-alzheimers-disease-franchise"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_4_31_1","unstructured":"ADUHELM\u00ae (aducanumab-avwa). package insert. Cambridge (MA): Biogen Inc.; 2022. https:\/\/www.biogencdn.com\/us\/aduhelm-pi.pdf"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-016-9722-5"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101339"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207919"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215148"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.34"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"e_1_3_4_40_1","unstructured":"Favre HA Powell WH. Nomenclature of organic chemistry. IUPAC recommendations and preferred names. Royal Society of Chemistry; 2013. https:\/\/iupac.qmul.ac.uk\/BlueBook\/"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03654836"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080576"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000244346.08950.64"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00484-8"},{"issue":"1","key":"e_1_3_4_45_1","first-page":"28","article-title":"Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy","volume":"8","author":"Gervais F","year":"2001","unstructured":"Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001 Jul;8(Suppl 1):28\u201335.","journal-title":"Amyloid"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00614"},{"key":"e_1_3_4_47_1","unstructured":"Alzheon Inc. Alzheon launches with veteran team and funding to accelerate drug development in Alzheimer\u2019s disease and other neurodegenerative disorders 2013. [cited 2023 Mar 14]. Available from: https:\/\/alzheon.com\/alzheon-launches-with-veteran-team-and-funding-to-accelerate-drug-development-in-alzheimers-disease-and-other-neurodegenerative-disorders\/"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2016.115"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2017.26"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2011.20612"},{"key":"e_1_3_4_51_1","unstructured":"Alzheon Inc. Sustained clinical effects of tramiprosate in APOE4\/4 homozygous patients with Alzheimer\u2019s disease over 130 weeks: results of phase 3 extension study. 2017 [cited 2023 Mar 14]. Available from: https:\/\/alzheon.com\/clinical-effects-tramiprosate-apoe4-homozygotes-mild-moderate-alzheimers-disease-ad-sustained-130-weeks-results-phase-3-extension-study\/"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0608-3"},{"key":"#cr-split#-e_1_3_4_53_1.1","unstructured":"Alzheon Inc. An efficacy and safety study of ALZ-801 in APOE4\/4 early AD subjects: ClinicalTrials.Gov. [updated 2021 May 19"},{"key":"#cr-split#-e_1_3_4_53_1.2","unstructured":"cited 2021 March 14]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04770220"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0434-z"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0554-0"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn3000247"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804758106"},{"key":"e_1_3_4_58_1","volume-title":"15th Conference Clinical Trials Alzheimer\u2019s Disease","author":"Abushakra S","year":"2022","unstructured":"Abushakra S, Hey J, Blennow K, et al., editors. OC27-Significant effects of oral ALZ-801 on plasma biomarkers of Alzheimer\u2019s disease: 12-month interim analysis of phase 2 biomarker study in APOE4 carriers with early AD. In: 15th Conference Clinical Trials Alzheimer\u2019s Disease; San Francisco, USA. The Journal of Prevention of Alzheimer\u2019s Disease; 2022."},{"key":"e_1_3_4_59_1","unstructured":"Alzheon Inc. Biomarker effects of ALZ-801 in APOE4 carriers with early Alzheimer\u2019s disease 2020 [updated 2020 Sep 30 [cited 2023 Mar 14]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04693520"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.069141"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203129"},{"key":"e_1_3_4_64_1","volume-title":"15th Annual Clinical Trials in Alzheimer\u2019s Disease Conference","author":"Alzheon Inc","year":"2022","unstructured":"Alzheon Inc. Alzheon to present industry-leading biomarker, brain preservation, and clinical effects with oral ALZ-801 (valiltramiprosate). In: 15th Annual Clinical Trials in Alzheimer\u2019s Disease Conference; 2022 [cited 2023 Mar 14]. Available from: https:\/\/alzheon.com\/alzheon-to-present-industry-leading-biomarker-brain-preservation-and-clinical-effects-with-oral-alz-801-valiltramiprosate-at-15th-annual-clinical-trials-in-alzheimers-disease-conference\/"},{"issue":"1","key":"e_1_3_4_65_1","first-page":"S8","article-title":"November 29- December 2, 2022, San Francisco, USA: Symposia - Oral Communications - Late Breaking News","volume":"9","author":"Abstract: 15th Conference Clinical Trials Alzheimer\u2019s Disease","year":"2022","unstructured":"Abstract: 15th Conference Clinical Trials Alzheimer\u2019s Disease. November 29- December 2, 2022, San Francisco, USA: Symposia - Oral Communications - Late Breaking News. J Prev Alzheimers Dis. 2022;9(S1):S8\u2013S50.","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_3_4_66_1","unstructured":"Alzheon Inc. Alzheon announces early completion of enrollment of apolloe4 phase 3 clinical trial evaluating oral ALZ-801 (valiltramiprosate) in APOE4\/4 homozygotes with early Alzheimer\u2019s disease. 2022 [cited 2023 Mar 14]. Available from: https:\/\/alzheon.com\/alzheon-announces-early-completion-of-enrollment-of-apolloe4-phase-3-clinical-trial-evaluating-oral-alz-801-valiltramiprosate-in-apoe4-4-homozygotes-with-early-alzheimers-disease\/"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01312"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.08.008"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200892"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2429"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2360069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:02:52Z","timestamp":1727244172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2360069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.1080\/14656566.2024.2360069"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2360069","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}